Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors

By sjmartinez • May 14, 2025

Korecki JRT, Slavich GM, Ganz PA, Irwin MR, Cole S, Crespi CM, Bower JE. Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors. Biopsychosoc Sci Med. 2025 May 9. doi: 10.1097/PSY.0000000000001398. Epub ahead of print. PMID: 40359350.

Tags: and Energy study, BMI, body mass index, breast cancer survivors, C-reactive protein, CBT-I, Center for Epidemiological Studies Depression Scale, CES-D, CI, cognitive behavioral therapy for insomnia, confidence interval, CRP, depression, Hematology/Oncology, IL-6, Inflammation, interleukin, Life Orientation Test-Revised, lifetime stressor exposure, LOT-R, PA, physical activity, Pittsburgh Sleep Quality Index, PSQI, Publications, Research on Inflammation, resilience, RISE, SD, standard deviation, Strain, Stress, Stress and Adversity Inventory, TNF-α, Tumor necrosis factor-α

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]

The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond

Chauhan A, Hendifar AE, El-Haddad G, Soares HP, Herrmann K. The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate[...]

CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer

Alcantar JM, Chuang FL, Kim DD. CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer. Cureus. 2026 Mar 25;18(3):e105839. doi: 10.7759/cureus.105839. PMID: 42037944; PMCID: PMC13108622.